As such, we have sought to evaluate how levels of pre-existing T cell infiltrate might affect response to combined PARP and WEE1 inhibitors as well as if the combined treatment could stimulate a more immune-inflamed tumour microenvironment conducive for therapeutic response to immune checkpoint inhibitors. Here, WEE1 is linked to neoplasm.